Category → Women in Science and Medicine
My apologies to regular readers and my colleagues at C&EN for my month-long silence at the blog. I saw cobwebs on my laptop screen when I opened the back end this morning. Part of my hiatus came from complications of an infected molar extraction and my inability to concentrate. I’ve also been trying to take short Internet holidays over the last two months because all of the political nonsense in my state is negatively affecting my mental health.
But the tooth canyon is about 50% healed and our state legislature has finished, for now, shifting progressive North Carolina toward its pre-Research Triangle Park level of ignorance, racism, and poverty.
During this month, I came across an excellent post on the Scientific American
Yonath, a structural chemist recognized for her extensive work in showing how the ribosome catalyzes protein synthesis, has generally not made much of the fact that she’s only the fourth woman to receive the Nobel Prize in Chemistry, and the first since Dorothy Hodgkin in 1964.
As I did back in 2009 when interviewing Yonath at the North Carolina Biotechnology Center, Raven debates whether focusing on Yonath as a female scientist is a good thing for the cause of women scientists. Should we focus only on the accomplishments? Or should we focus on her accomplishments in the context of the distinct barriers often facing women scientists?
I’m equally torn, particularly since my 20-year laboratory career was advanced by a group that consistently ranged from 75% to 100% women. I never specifically recruited women to my laboratory but it seems that they might have self-selected for reasons not known to me. My activism in diversity in science extends back to my pharmacy faculty days at the University of Colorado where I assisted in selecting minority scholarship recipients for a generous program we had from the Skaggs Family Foundation.
The goings-on in North Carolina politics is not germane to this scientific discussion. We can speak all we want about our modern society being post-racial and having more women leaders than ever. But voter laws that disproportionately disenfranchise African-Americans and legislation that severely compromises women’s reproductive health tells me that we still need to pay attention to the influence of racial and gender attitudes.
Heck, even our Governor Pat McCrory showed his true colors yesterday while protestors, primarily women, were holding a vigil marking his signature of restrictive abortion legislation: He stepped out of the governor’s mansion to give protestors a plate of cookies and quickly returned behind the iron gates without any substantive engagement.
I’d be interested to hear from GlobCasino and C&EN readers after reading my own interview with Ada Yonath. Should we still be making an issue of advances in race, gender, and sexual orientation in chemistry?
I think yes, and it’s never been more important.
This post appeared originally on 14 December 2009 at the ScienceBlogs.com home of Terra Sigillata.
Last week in Stockholm (and Oslo), the 2009 Nobel Prize winners were gloriously hosted while giving their lectures and receiving their medals and diplomas. In Chemistry this year, the Nobel was shared by Venkatraman Ramakrishnan, Thomas A Steitz, and Ada E Yonath for their studies on the structure and function of the ribosome, a remarkable nucleoprotein complex that catalyzes the rapid, coordinated formation of peptide bonds as instructed by messenger RNA. My post on the day of the announcement in October was designed to counter the inevitable (and now realized) criticisms that the prize was not for “real” chemistry.
Only ten days later, we in the NC Research Triangle area were very fortunate to host Dr Yonath at the North Carolina Biotechnology Center for the Symposium on RNA Biology VIII, sponsored by The RNA Society of North Carolina.
Among the many noteworthy speakers was Dr Greg Hannon from Cold Spring Harbor Laboratory, a scientist who some feel was overlooked for the 2006 Nobel Prize in Medicine or Physiology, one where Andrew Fire and Craig Mello were recognized for RNA interference and gene silencing.
NC Biotech’s Senior Director of Corporate Communication, Robin Deacle, kindly invited me to an audience with Dr Yonath and two science reporters following Dr Yonath’s lecture. As you might suspect, I was quite honored to visit for awhile with the woman who defied the naysayers and successfully crystallized a bacterial ribosome, then used X-ray crystallography to determine its structure below three angstroms resolution. The fact that she also used natural product antibiotics to stabilize ribosomal structure added to my magnitude of admiration.
Continue reading →
Earlier last month, you may have seen a beautiful set of images by Austin-based wedding and lifestyle photographer Jaime C. Moore. To celebrate the 5th birthday of her daughter Emma, Moore wrote:
Set aside the Barbie dolls and Disney princesses for just a moment and let’s show our girls the real women they can be.
Moore then had Emma do some five-year-old dressing and posing, but in character of some major female role models throughout history:
Susan B. Anthony, Amelia Earhardt, Coco Chanel, Helen Keller, and Jane Goodall.
We’re about to close up the world headquarters of Terra Sigillata to head out and convene with the PharmFamily in points north for Easter (but, thankfully, not a Nor’easter.)
Before we do, I’d like to draw your attention to a short but astute editorial in The Chronicle of Higher Education by chemist Gina Stewart. Stewart launches her essay with a concise description of a dichotomy that’s giving all of us agita:
The STEM paradox: At a time when we have a national dialogue about the dearth of students pursuing these degrees, newly minted Ph.D.’s are having a harder time landing academic jobs.
She then talks about her career and what she considers to be the shortest postdoc on record (believe me, Gina, I know of many shorter) in the UNC-Chapel Hill laboratory of Joe DeSimone. There, the seeds were planted for entrepreurship and a fascination with the practical applications of carbon dioxide.
Years later, Stewart is now CEO of Arctic, Inc., a company that uses sustainable weed control methods by selectively freezing these nasty invasive threats to biodiversity – her company site is appropriately named frostkills.com.
Her experience is one example where one takes a different approach to a chemistry career than following in the traditional academic progression. The first commenter already admonished her for saying that she was pursuing an alternative career. Based on percentages, being a tenure-track faculty member is now the alternative.
It’s a great read so enjoy. I was also delighted to learn that she and her husband live just west of the Research Triangle and base their company in Clemmons, NC.
One of science journalism’s expert voices, author Maryn McKenna, will be the guest on this Thursday’s ACS Webinar Joy of Science series at 2:00 – 3:00 pm Eastern time.
Free, as always, you can sign up to participate at this link.
McKenna’s book, SUPERBUG: The Fatal Menace of MRSA, is a thorough and accessible investigation of the reemergence of lethal bacterial infections while new drug development lags.
The book, now in paperback, received the 2011 Science in Society Award from the the National Association of Science Writers.
McKenna had spent much of her career at the Atlanta Journal-Constitution as the only U.S. reporter assigned full time to the Centers for Disease Control and Prevention. In fact, her first book, Beating Back the Devil, detailed her experiences with CDC’s Epidemic Investigation Service (EIS), the team dispatched anywhere in the world that’s experiencing an unusual infectious disease event.
From her book’s website:
I was following a group of disease detectives from the Centers for Disease Control and Prevention, the CDC, through an investigation of bizarre skin infections in Los Angeles. The CDC wanted to know where men were picking them up. I wanted to know something more fundamental: How could a minor problem — something that the victims all described as looking like a tiny spider bite — blow up into massive infections that ate away at skin and muscle, put people into the hospital for weeks and drained their health and their bank accounts? Where had it come from? And if it could do that, what else was it capable of?
Maryn’s one of the best science writers in the world in terms of mastering her subject and making it widely accessible.
Of course, her webinar will be of interest to anyone concerned about the proliferation of drug-resistant infectious diseases and how to design drugs to stay a step ahead of evolution.
But she’s also a great model to emulate for anyone trying to make their scientific work more approachable to non-experts. You might even learn a thing or two about telling a gripping story.
And, thanks to your American Chemical Society, dialing into the webinar is FREE. Go here to register.
You don’t even need to be an ACS member!
You can thank me later.
The webinar will be archived but you can also hear from Maryn McKenna on a regular basis at her Wired Science blog, Superbug and on Twitter @marynmck.
This question came to me as I read last week’s C&EN cover story by Dr. Lauren K. Wolf on caffeine toxicity entitled, “Caffeine Jitters.”
By the way, read it if you haven’t — it’s open-access on C&EN right now and remains the most-read (last 7 days), most-commented (last 30 days), and most-shared (last 30 days) article since it appeared. Lauren did a terrific job of sifting through decades of information on the physiological effects of caffeine to make sense out of the true health hazards of caffeine consumption at “normal” and excessive doses.
Caffeine, a natural alkaloid found predominantly in coffee beans, is 1,3,7-trimethylxanthine (not IUPAC, but you get it). In the body, the hepatic cytochrome P450 CYP1A2 catalyzes the N-demethylation of caffeine to theophylline, theobromine, and paraxanthine.
Of note, theobromine and theophylline also occur in nature. Theobromine is found in cacao beans. Because chocolate is heavenly, it was given the Greek name for “food of the gods”: theos – god; broma – food.
Correct, theobromine contains no bromine. Had it contained bromine, the name might have been the same but would have been derived from the Greek bromos, or “stench” – “stench of the gods,” which, clearly, it is not.
Theophylline also occurs naturally and had been extensively used as a bronchodilator for folks with asthma. Primatene tablets used to contain theophylline but today are ephedrine. Again, theophylline has the godly theo- prefix while the -phylline suffix indicated that it comes from leaves.
And apologies to paraxanthine. It’s known historically for having first been isolated from urine in 1883. Not until the 1980s was it shown to occur in some plants. In any case, the biosynthesis of the di- and tri-methylxanthines originate with xanthosine from purine metabolism.
So to my question. . .
Because caffeine is so widely worshiped, why is it not known as theoanaleptine? The Greek analeptikos means stimulant and the English term analeptic is defined as a stimulant drug.
So, why not?
My best guess is because caffeine was described in the literature prior to theophylline and theobromine. From M.J. Arnaud’s chapter in Caffeine (Springer, 1984):
The isolation of caffeine from green coffee beans was described in Germany in 1820 by Runge and confirmed the same year by von Giese. In France, Robiquet in 1823 and then Pelletier in 1826 independently discovered a white and volatile crystalline substance. The name “cofeina” appeared in 1823 in the “Dictionaire des termes de medécine” and the word “caffein” or “coffein” was used by Fechner in 1826.
Arnaud goes on to say that theobromine was discovered in cocoa beans in 1842 and theophylline in tea leaves in 1888.
So, caffeine had about a two-decade headstart in being named for its presence in coffee before related methylxanthines took on their divine monikers.
Sure, sure, caffeine is a well-recognized name that derives predictably from its source. But let’s live a little. Wouldn’t you rather be drinking the stimulant of the gods?
If you’re as excited about this as I am, you may purchase theoanaleptine coffee mugs here. They’ll set you apart from ever Tom, Dick, and Harriet who think they’re clever with their caffeine coffee mugs.
And even with accepting the new colloquial name of theoanaleptine, our friend Scicurious can still keep her tattoo unchanged.
Our best wishes to all of you in the Northeast getting ready for Hurricane Sandy. I understand that even DC is closed today. So if you still have power at home, let me share a bit of levity with you.
Over the weekend I learned that my science writing student, Meghan Radford (@meradfor), had a clever piece published at mental_floss, the magazine and website, “where knowledge junkies get their fix.”
Megan’s article entitled, “18 Gene Names that Cover the Gamut, From Movies to Pop Culture to Cartoons,” illustrates the comical yet discordant and unscientific process behind naming genes.
Her article reminded me of C&EN’s Carmen Drahl when she wrote about named reactions in both the magazine (C&EN, 17 May 2010) and her Newscripts blog here at GlobCasino.
I’m not familiar with any genes that are named after the person who discovered them but, as Radford points out, a great many have been given interesting colloquial names. International gene nomenclature organizations exist but the standardized rules of these committees still make refer to the less formal names.
I’m not an architect but I absolutely love quirky and creative buildings. During the eight years I lived in the foothills outside of Denver, I passed the clamshell-shaped home featured in Woody Allen’s 1973 movie, “Sleeper” – yes, the home with the Orgasmatron (a prop made from a cylindrical door like those used for research darkrooms).
For you youngsters who may not know what I’m talking about, here’s a two-minute movie clip that’s probably safe for work.
Well, from that era is another futuristic building designed by Paul Rudolph and completed in 1971 — then known as the Burroughs-Wellcome Headquarters Building in Research Triangle Park.
Those of you who do chemistry in colleges of pharmacy are used to discussions of how your graduates can truly use their Doctor of Pharmacy training. You’ve probably often wondered why your students spend so much time in clinical pharmacy when more than half of them end up in community pharmacy, a model that has largely kept its sweatshop-like workflow (the “counseling booth” at my local pharmacy has cobwebs for the simple reason that pharmacists cannot be reimbursed for cognitive services.)